Literature DB >> 2013150

Fibrocellular tissue response after percutaneous transluminal coronary angioplasty. An immunocytochemical analysis of the cellular composition.

M Ueda1, A E Becker, T Tsukada, F Numano, T Fujimoto.   

Abstract

BACKGROUND: Restenosis after initial, successful percutaneous transluminal coronary angioplasty (PTCA) is due to fibrocellular proliferation. METHODS AND
RESULTS: The present study focused on the nature of fibrocellular tissue in humans by use of immunocytochemical techniques. Four hearts (five coronary arteries) were investigated; time lapse between PTCA and death varied between 20 days (two arteries) and 1 year 7 months. Proliferating cells stained positive with smooth muscle cell-specific monoclonal antibodies. Cells from early proliferative lesions (20 days) have a phenotypic expression different from cells in "old" lesions. Proliferating cells stained positive with vimentin but were negative with desmin, irrespective of the lesion's age.
CONCLUSIONS: The findings indicate a change in actin isoform expression of smooth muscle cells while adapting to a pathological state.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013150     DOI: 10.1161/01.cir.83.4.1327

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

1.  Dynamics of Vascular Remodeling: An Overview and Bibliography.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  Phenotypic change and accumulation of smooth muscle cells in strictures in Crohn's disease: relevance to local angiotensin II system.

Authors:  Takehisa Suekane; Yoshihiro Ikura; Kenji Watanabe; Junko Arimoto; Yoko Iwasa; Yoshimi Sugama; Soichiro Kayo; Kenichi Sugioka; Takahiko Naruko; Kiyoshi Maeda; Kosei Hirakawa; Tetsuo Arakawa; Makiko Ueda
Journal:  J Gastroenterol       Date:  2010-04-02       Impact factor: 7.527

3.  Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study.

Authors:  S Tanizawa; M Ueda; C M van der Loos; A C van der Wal; A E Becker
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

4.  Acute cellular damage in medial smooth muscle cells following experimental coronary angioplasty in dog. Damage of cytoskeleton and apoptosis.

Authors:  J Ogawa; H Fujiwara; A Kawamura; M Katsuragawa; T Htay; T Fujiwara; K Hasegawa; K Yamasaki; M Tanaka; S Sasayama
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

5.  Proliferative response of human and minipig smooth muscle cells after coronary angioplasty to growth factors and platelets.

Authors:  C Unterberg; T Meyer; V Wiegand; H Kreuzer; A B Buchwald
Journal:  Basic Res Cardiol       Date:  1996 Nov-Dec       Impact factor: 17.165

6.  Role of endothelial cell denudation and smooth muscle cell dedifferentiation in neointimal formation of human vein grafts after coronary artery bypass grafting: therapeutic implications.

Authors:  Y Sasaki; S Suehiro; A E Becker; H Kinoshita; M Ueda
Journal:  Heart       Date:  2000-01       Impact factor: 5.994

7.  Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries.

Authors:  R Riessen; J M Isner; E Blessing; C Loushin; S Nikol; T N Wight
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

8.  Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization.

Authors:  J G Pickering; L Weir; J Jekanowski; M A Kearney; J M Isner
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 9.  Pharmacological approaches to the prevention of restenosis after coronary angioplasty.

Authors:  M Hamon; E Lécluse; J P Monassier; G Grollier; J C Potier
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

10.  Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for the epidermal growth factor receptor.

Authors:  J G Pickering; P A Bacha; L Weir; J Jekanowski; J C Nichols; J M Isner
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.